|
|
| Titles |
1993 Canadian Journal of Psychiatry Roxiam |
| Related Item |
|
| Genre |
medicine |
| Genre |
medicines (psychiatric) |
| Identifier |
cjp1993aug_sep_oct_nov_dec18 |
| Note |
For years they've been called 'acceptable' side effects. Now a new drug can change all that. Introducing Roxiam. An advance in the treatment of schizophrenia. For years effective management of schizophrenia has often come at a terrible price. Extrapyramidal symptoms, especially severe tremors, akathisia and rigidity remain troubling roadblocks. But now a new atypical neuroleptic with efficacy equal to haloperidol means there can be a clearer path to recovery. New Roxiam (remoxipride), with its highly selective pharmacological action of bloking D2 receptors, has consistently shown to be effective in controlling both the positive and negative symptoms in schizophrenia, with reduced adverse effects compared to haloperidol. Clinical trials have shown that adverse reactions are less frequent and often less severe with Roxiam treated patients than those treated with haloperidol. Studies have further shown that anticholinergic medications were less frequently prescribed as concomitant medication in order to counteract adverse extrapyramidal reactions in the Roxiam groups than among haloperidol recipients. With Roxiam, the management of schizophrenia takes and important stride forward. And the ground gained was worth the wait. Roxiam helps separate the benefits of control from the burden of side effects. |
| Abstract |
Remoxipride, Astra, A blurry image of a man dressed in black, looking toward the ground, with his hands together as they appear to be shaking. Also pictured is a graph comparing side effects. The Roxiam logo is a pink and blue object put together to make a cube. |
